4,428
edits
Pantheon Industries: Difference between revisions
m
no edit summary
mNo edit summary Tag: 2017 source edit |
mNo edit summary |
||
| Line 3: | Line 3: | ||
| logo = Pantheon-logo.png | | logo = Pantheon-logo.png | ||
| type = Private | | type = Private | ||
| industry = | | industry = | ||
{{flatlist| | |||
* Chemical | * Chemical | ||
* Life-science | * Life-science | ||
| Line 9: | Line 10: | ||
* Pharmaceutical | * Pharmaceutical | ||
* Energy | * Energy | ||
}} | |||
| fate = | | fate = | ||
| predecessor = <!-- or: | predecessors = --> | | predecessor = <!-- or: | predecessors = --> | ||
| Line 20: | Line 22: | ||
| products = | | products = | ||
| owner = <!-- or: | owners = --> | | owner = <!-- or: | owners = --> | ||
| num_employees = 100,000 | | num_employees = 100,000 | ||
| num_employees_year = <!-- Year of num_employees data (if known) --> | | num_employees_year = <!-- Year of num_employees data (if known) --> | ||
| parent = | | parent = | ||
}} | }} | ||
'''Pantheon Industries''' is a multinational conglomerate based in [[Caphiria]]. It acts as main holding company for a number of subsidiaries, offering products in the chemical, life-sciences, materials science, pharmaceuticals, and energy sector. Pantheon has 100,000 employees worldwide with | '''Pantheon Industries''' is a multinational conglomerate based in [[Caphiria]]. It acts as the main holding company for a number of subsidiaries, offering products in the chemical, life-sciences, materials science, pharmaceuticals, and energy sector. Pantheon has 100,000 employees worldwide with annual revenues of $90 billion. | ||
Pantheon emerged in the | Pantheon emerged in the 1880s from the Katta Fishing Corp. which had gained immense value after gaining a monopoly on the global tuna market by exploiting fishing zones in the Omnian Sea. It was owned by Georgis Kattapoulos who had previously published his philosophical work "Society at the Dawn of the 20th Century", after which he began to restructure his company, rebranding it to Pantheon while beginning to acquire not only smaller competitors but also businesses which he deemed visionary or "seminal for society". By the time of Georgis' death in 1922, Pantheon had incorporated nearly all agricultural and life-science companies until an antitrust suit forced the company to split apart in 1977. | ||
Today, Pantheon Industries has diversified its portfolio and is still dominant in the pharmaceutical, chemical, and bio-science sectors. The current chairman of Pantheon Industries is Oiksi Iivostner, who was appointed in 2021 after the ousting of the former chairman Bob Dole. | Today, Pantheon Industries has diversified its portfolio and is still dominant in the pharmaceutical, chemical, and bio-science sectors. The current chairman of Pantheon Industries is Oiksi Iivostner, who was appointed in 2021 after the ousting of the former chairman Bob Dole. | ||
| Line 33: | Line 35: | ||
=== Subsidiaries === | === Subsidiaries === | ||
* Katta Seafood - Founded in 1887, Katta Seafood traces its origin to the original company that Pantheon was | * Katta Seafood - Founded in 1887, Katta Seafood traces its origin to the original company that Pantheon was built around. Today, it is one of the largest seafood companies in Caphiria and sells frozen, canned, smoked, and ready-to-eat seafood products for the wholesale, retail and foodservice markets under a variety of different brand names. | ||
* Pharmonis - Founded in 1922, Pharmonis is a pharmaceutical company that mainly operates in the acquisition (for repricing), manufacturing, and sale of consumer healthcare products, generic prescription drugs, and active pharmaceutical ingredients (APIs). In 1983, after concerns about tax evasion and an eventual inquiry from The Imperium, Pharmonis suffered its biggest one-day share price fall in its history. The loss equated equated to half of its market value, at which point Pantheon acquired Pharmonis. Today, the company operates in three segments; Consumer Healthcare, Rx Pharmaceuticals, and Active Pharmaceutical Ingredients. | * Pharmonis - Founded in 1922, Pharmonis is a pharmaceutical company that mainly operates in the acquisition (for repricing), manufacturing, and sale of consumer healthcare products, generic prescription drugs, and active pharmaceutical ingredients (APIs). In 1983, after concerns about tax evasion and an eventual inquiry from The Imperium, Pharmonis suffered its biggest one-day share price fall in its history. The loss equated equated to half of its market value, at which point Pantheon acquired Pharmonis. Today, the company operates in three segments; Consumer Healthcare, Rx Pharmaceuticals, and Active Pharmaceutical Ingredients. | ||
* Lyonardo - Founded in 1978, Lyonardo is a multinational biotechnology company based in Dreistengrad, [[Diamavya]] specializing in the discovery, development, and delivery of therapies for the treatment of neurodegenerative, hematologic, and autoimmune diseases to patients worldwide. Lyonardo owns the rights to Fumaderm and BG-12, an oral fumarate, which is being studied for the treatment of multiple sclerosis and psoriasis.It also owns the patent for a treatment for hemophilia B as well as the technology for developing inhalable treatments. Lyonardo is known for acquiring smaller biotech companies and poaching prominent biologists and has come under scrutiny for these aggressive tactics. It was acquired by Pantheon in 1993 for $3.25 billion. | * Lyonardo - Founded in 1978, Lyonardo is a multinational biotechnology company based in Dreistengrad, [[Diamavya]] specializing in the discovery, development, and delivery of therapies for the treatment of neurodegenerative, hematologic, and autoimmune diseases to patients worldwide. Lyonardo owns the rights to Fumaderm and BG-12, an oral fumarate, which is being studied for the treatment of multiple sclerosis and psoriasis.It also owns the patent for a treatment for hemophilia B as well as the technology for developing inhalable treatments. Lyonardo is known for acquiring smaller biotech companies and poaching prominent biologists and has come under scrutiny for these aggressive tactics. It was acquired by Pantheon in 1993 for $3.25 billion. | ||